help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strauchen, J. A.
Right arrow Articles by Breakstone, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strauchen, J. A.
Right arrow Articles by Breakstone, B. A.

American Journal of Pathology, Vol 126, 506-512, Copyright © 1987 by American Society for Investigative Pathology

REGULAR ARTICLES

IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases

JA Strauchen and BA Breakstone

Interleukin-2 (IL-2) receptor expression is a feature of T-cell activation and T-cell neoplasia. Expression of the IL-2 receptor in human lymphoid lesions was studied in a series of 166 immunophenotyped cases, including nodal and extranodal reactive lymphoid proliferations (44 cases), low-grade B-cell lymphomas (27 cases), intermediate and high grade B cell lymphomas (42 cases), peripheral T-cell lymphomas (13 cases), Hodgkin's disease (12 cases), histiocytic proliferations (15 cases), nonhematopoietic tumors (16 cases), and miscellaneous lesions (7 cases). Low levels of receptor expression were seen in reactive lymphoid lesions, low-grade B-cell lymphomas, and nonhematopoietic tumors (20%, 7%, and 25% of cases, respectively, with greater than 10% positive cells). High levels of receptor expression were seen in cases of peripheral T-cell lymphoma and histiocytic proliferations (86% and 100% of cases, respectively, with greater than 10% positive cells). Intermediate levels of expression were seen in Hodgkin's disease (including Reed-Sternberg cells) and some cases of intermediate and high-grade B-cell lymphomas (58% and 50% of cases, respectively, with greater than 10% positive cells). IL-2 receptor expression is not confined to T-cell neoplasia, but is also a feature of neoplastic and nonneoplastic histiocytic proliferations, Hodgkin's disease, and some intermediate and high-grade B-cell lymphomas. Biologic and therapeutic implications are discussed.


This article has been cited by other articles:


Home page
 BloodHome page
B. F. Skinnider and T. W. Mak
The role of cytokines in classical Hodgkin lymphoma
Blood, May 29, 2002; 99(12): 4283 - 4297.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Kreitman, W. H. Wilson, J. D. White, M. Stetler-Stevenson, E. S. Jaffe, S. Giardina, T. A. Waldmann, and I. Pastan
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
J. Clin. Oncol., April 1, 2000; 18(8): 1622 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen
Targeted toxins
Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 149 - 165.
[Abstract] [PDF]

Home page
 BloodHome page
A. Engert, V. Diehl, R. Schnell, A. Radszuhn, M.-T. Hatwig, S. Drillich, G. Schon, H. Bohlen, H. Tesch, M.-L. Hansmann, et al.
A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma
Blood, January 15, 1997; 89(2): 403 - 410.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Society for Investigative Pathology.